RC108 / Rongchang Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
RC108 / Rongchang Pharma
NCT05628857: A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor

Recruiting
2
240
RoW
RC108
RemeGen Co., Ltd.
Digestive Cancer
10/24
10/25
RC108-C004, CTR20232828: An open-label, single-arm, multicenter Phase Ib/II clinical study to evaluate the safety, tolerability, efficacy, and pharmacokinetic profile of RC108 in combination with toripalimab in patients with c-Met-expressing advanced solid tumors

Ongoing
1b/2
178
China
RC108 - Rongchang Pharma
Remegen Biopharmaceutical (Yantai) Co., Ltd
C-MET-expressing advanced solid tumors
 
 
NCT05821933: RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

Recruiting
1/2
106
RoW
RC108, Furmonertinib, Toripalimab
RemeGen Co., Ltd.
NSCLC
09/25
09/26

Download Options